ReviveRX
ReviveRX is a 503A compounding pharmacy based in Houston, TX. A government record names semaglutide and tirzepatide at ReviveRX; the newest is an FDA inspection report (Form 483) dated March 27, 2026. It fills prescriptions; it doesn’t write them, so you can’t get a GLP-1 from ReviveRX without a prescription from a licensed clinician.12
How to get a GLP‑1 filled by ReviveRXChecked November 20, 2026 against FDA, CMS and state board records. Every fact links to its source.
ReviveRX at a glance
How to get a GLP‑1 filled by ReviveRX
To get a GLP‑1 from ReviveRX, you first need a prescription: it fills prescriptions; it doesn’t write them or sell without one. An online program takes you through the steps: you fill in a health questionnaire, a licensed clinician reviews it, and if they prescribe, the program’s pharmacy ships the medication to you.
1 program we review names ReviveRX among its pharmacies; they’re listed below. These are the three programs ranked highest on our score.
- 1Health questionnaire, online
- 2A licensed clinician decides
- 3The pharmacy ships to you
We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money
Prefer your own clinician? You’re free to: ask them to send your prescription to ReviveRX or another licensed pharmacy.
See every program we rankWhat ties ReviveRX to GLP‑1s
- FDA inspection report (Form 483)March 27, 2026 · semaglutide and tirzepatideFDA Form 483 inspectional observations, Revive RX LLC, issued 2026-03-275
“Micrococcus luteus during production of Tirzepatide Lot #s 14031295”
- Court recordMarch 10, 2026 · semaglutide and tirzepatideRevive Rx, LLC v. Reed Hoelscher, memorandum opinion and order (pharmacy as plaintiff)6
“Plaintiff focuses its business on compounding weight loss medications, including semaglutide and tirzepatide.”
- Court recordDecember 15, 2025 · tirzepatideEli Lilly and Company v. Revive Rx, LLC, memorandum and opinion7
“Revive, a nationwide pharmacy, dispenses tirzepatide products to many of its patients.”
- FDA inspection report (Form 483)February 7, 2025 · semaglutide and tirzepatideFDA Form 483 inspectional observations, Revive RX LLC, issued 2025-02-078
“Semaglutide 5mg/ml 2cc, Lot 10453555 BUD 4/27/2025”
- FDA recallApril 20, 2024 · tirzepatideClass I recall D-0511-2024: Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionate9
“Tirzepatide 10 mg/0.5 mL Sterile Solution, 2 mL Multi-dose vial, Rx only, This is a Compounded Product By: Revive RX Pharmacy, 3831 Golf Dr A, Houston, TX 77018, internally assigned NDC 99000-9278-64”
- FDA recallMay 11, 2023 · tirzepatideClass II recall D-0771-2023: Sub-potent Drug10
“Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial, Rx Only, For Sub-Q Use Only, Compounded Drug Product By: Revive Rx, 3831 Golf Dr A, Houston, TX 77018, NDC: 99000-9278-64.”
ReviveRX’s FDA record
| Date | What the FDA did |
|---|---|
| March 27, 2026 | 483 Issued 3/27/202611 |
| September 22, 2025 | Warning Letter Issued 09/22/202512 |
| February 7, 2025 | 483 Issued 02/07/202513 |
| January 22, 2025 | FMD-145 Letter Issued 01/22/2025 |
| June 30, 2023 | Untitled Letter Issued 06/30/202314 |
| May 4, 2022 | 483 Issued 05/04/202215 |
| August 6, 2021 | 483 Issued 08/06/202116 |
Telehealth programs that use ReviveRX
What a compounded GLP‑1 is, and what it isn’t
The bigger question with any compounded program is the drug itself. Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.2526 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.2417
ReviveRX: questions
- 1.ReviveRX: what it says it isreviverx.comretrieved 2026-11-20↩“ReviveRX is a licensed 503A mail-order compounding pharmacy”
- 2.NPI Registry: REVIVE RX LLC (NPI 1285189076)Centers for Medicare & Medicaid Servicesretrieved 2026-11-20↩
- 3.NPI Registry: REVIVE RX LLC (NPI 1437600392)Centers for Medicare & Medicaid Servicesretrieved 2026-11-20
- 4.Belle, a GLP-1 telehealth program, names it among its pharmaciesBelleretrieved 2026-10-26↩“ReviveRX, Houston, TX”
- 5.FDA Form 483 inspectional observations, Revive RX LLC, issued 2026-03-27FDAretrieved 2026-03-27↩“Micrococcus luteus during production of Tirzepatide Lot #s 14031295”
- 6.Revive Rx, LLC v. Reed Hoelscher, memorandum opinion and order (pharmacy as plaintiff)U.S. District Court for the Northern District of Texasretrieved 2026-03-10↩“Plaintiff focuses its business on compounding weight loss medications, including semaglutide and tirzepatide.”
- 7.Eli Lilly and Company v. Revive Rx, LLC, memorandum and opinionU.S. District Court for the Southern District of Texasretrieved 2025-12-15↩“Revive, a nationwide pharmacy, dispenses tirzepatide products to many of its patients.”
- 8.FDA Form 483 inspectional observations, Revive RX LLC, issued 2025-02-07FDAretrieved 2025-02-07↩“Semaglutide 5mg/ml 2cc, Lot 10453555 BUD 4/27/2025”
- 9.Class I recall D-0511-2024: Labeling: Label Mix-up - product labeled as tirzepatide contains testosterone cypionateU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2024-04-20↩“Tirzepatide 10 mg/0.5 mL Sterile Solution, 2 mL Multi-dose vial, Rx only, This is a Compounded Product By: Revive RX Pharmacy, 3831 Golf Dr A, Houston, TX 77018, internally assigned NDC 99000-9278-64”
- 10.Class II recall D-0771-2023: Sub-potent DrugU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2023-05-11↩“Tirzepatide 10 mg/0.5 mL Sterile Solution-2 mL Vial, Rx Only, For Sub-Q Use Only, Compounded Drug Product By: Revive Rx, 3831 Golf Dr A, Houston, TX 77018, NDC: 99000-9278-64.”
- 11.FDA: 483 Issued 3/27/2026 (PDF - 1.42 MB)U.S. Food and Drug Administration↩
- 12.FDA: Warning Letter Issued 09/22/2025U.S. Food and Drug Administration↩
- 13.FDA: 483 Issued 02/07/2025 (PDF - 1.47MB)U.S. Food and Drug Administration↩
- 14.FDA: Untitled Letter Issued 06/30/2023 (PDF - 256KB)U.S. Food and Drug Administration↩
- 15.FDA: 483 Issued 05/04/2022 (PDF - 2.5MB)U.S. Food and Drug Administration↩
- 16.FDA: 483 Issued 08/06/2021 (PDF - 447KB)U.S. Food and Drug Administration↩
- 17.Compounding inspections, recalls, and other actionsU.S. Food and Drug Administrationretrieved 2026-11-20↩
- 18.Texas license lookuppharmacy.texas.gov↩
- 19.Colorado license lookupapps2.colorado.gov↩
- 20.Florida license lookupmqa-internet.doh.state.fl.us↩
- 21.Arizona license lookupazbop.igovsolution.net↩
- 22.Missouri license lookupmopro.mo.gov↩
- 23.ReviveRX: where it shipsreviverx.comretrieved 2026-11-20↩“shipping to 45 states”
- 24.Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration↩
- 25.
- 26.
A pharmacy’s record can change after the day we read it: check its license with its state board before you fill a prescription. An FDA document is an allegation or an observation the FDA has published, not a court finding. This page is educational and is not medical advice.